Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis

M. Cattaneo, P. M. Tenconi, I. Alberca, V. V. Garcia, P. M. Mannucci

Research output: Contribution to journalArticlepeer-review

Abstract

The intravenous infusion of 1-deamino-8-D-arginine vasopressin (DDAVP) shortens the prolonged bleeding time in patients with congenital or acquired bleeding disorders, including patients with uremia or liver cirrhosis. We carried out a double-blind, placebo-controlled crossover study in ten patients with liver cirrhosis to evaluate whether or not their prolonged bleeding times could be shortened by subcutaneous injections of DDAVP (0.3 μg/kg), a more practical route of administration than intravenous infusions. One hour after DDAVP injection the bleeding time was significantly shortened (p <0.05). After 4 h, however, the bleeding time shortening was no longer statistically significant. There was no bleeding time change after placebo. Plasma levels of von Willebrand factor antigen (vWF:Ag) did not significantly increase after DDAVP or placebo. The study shows that subcutaneous DDAVP is an alternative method for short-term shortening of the bleeding time in liver cirrhosis.

Original languageEnglish
Pages (from-to)358-360
Number of pages3
JournalThrombosis and Haemostasis
Volume64
Issue number3
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis'. Together they form a unique fingerprint.

Cite this